"id","instanceType","rationale","description","uuid:ID","name","label"
"StudyDesign_1","StudyDesign","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","The main design for the study","53b5b846-bced-4edc-9f66-99ada147e56e","Study Design 1",""
